Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Palatin Technologies, Inc. (PTN)

2.9108   0.031 (1.07%) 03-22 10:54
Open: 2.96 Pre. Close: 2.88
High: 3.02 Low: 2.9
Volume: 8,497 Market Cap: 35(M)

Technical analysis

as of: 2023-03-22 10:48:41 AM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 4.02     One year: 4.73
Support: Support1: 2.46    Support2: 2.05
Resistance: Resistance1: 3.44    Resistance2: 4.05
Pivot: 2.82
Moving Average: MA(5): 2.74     MA(20): 2.84
MA(100): 3.6     MA(250): 5.94
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 32.7     %D(3): 20.4
RSI: RSI(14): 49.8
52-week: High: 13  Low: 0.27
Average Vol(K): 3-Month: 90 (K)  10-Days: 61 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PTN ] has closed below upper band by 28.1%. Bollinger Bands are 53.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.99 - 3.01 3.01 - 3.03
Low: 2.46 - 2.48 2.48 - 2.5
Close: 2.85 - 2.88 2.88 - 2.91

Company Description

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

Headline News

Thu, 02 Mar 2023
Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's ... - PR Newswire

Wed, 01 Mar 2023
Should You Buy Palatin Technologies, Inc. (PTN) Stock on Wednesday? - InvestorsObserver

Tue, 28 Feb 2023
Palatin Technologies (PTN) Issued Patent on Vyleesi For ... -

Wed, 15 Feb 2023
Healthcare Stocks on the Move Wednesday: SERA, TNON, ONVO, PTN, GLYC, CFRX, GRTX, TRDA - InvestorsObserver

Wed, 15 Feb 2023
Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update - Yahoo Finance

Wed, 18 Jan 2023
Palatin Receives $4.7 Million of Non-Dilutive Funding - PR Newswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  AMEX
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 231 (M)
% Held by Insiders 2.2711e+008 (%)
% Held by Institutions 4.3 (%)
Shares Short 4,770 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -3.22e+007
EPS Est Next Qtl 0
EPS Est This Year -0.35
EPS Est Next Year -0.06
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -12
Return on Assets (ttm) 429
Return on Equity (ttm) -25.1
Qtrly Rev. Growth 259440
Gross Profit (p.s.) 0
Sales Per Share -72.13
EBITDA (p.s.) -1.56e+007
Qtrly Earnings Growth -0.2
Operating Cash Flow 0 (M)
Levered Free Cash Flow -33 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.05
Price to Cash Flow 13.26

Stock Dividends

Dividend 0
Forward Dividend 1.149e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.